Scalable Biotech Manufacturing Unlocks a $14B Market
Fate Therapeutics, Inc. (FATE)
Last fate therapeutics, inc. earnings: 3/2 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.fatetherapeutics.com/investor-relations
Company Research
Source: PR Newswire
Issued on behalf of Avaí Bio, Inc.VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflection point. It's projected to surpass $7 billion in 2026 and reach $14 billion by 2035[1], driven by over 1,000 active clinical candidates globally. To keep up with this massive demand, the FDA just stepped in with new flexibility measures for cell and gene therapies[2]. By easing manufacturing requirements from the lab to commercial launch, regulators are accelerating the timeline for life-saving product approvals. This historic shift toward scalable bioproduction infrastructure is creating deep, sustainable value across a new class of durable therapy developers, including Avaí Bio (OTCQB: AVAI), ImmunityBio (NASDAQ: IBRX), Fate Therapeutics (NASDAQ: FATE), Fractyl Health (NASDAQ: GUTS), and Moleculin Biotech (NASDAQ: MBRX).Wall Street and industry analysts have already identified tight biologics cap
Show less
Read more
Impact Snapshot
Event Time:
FATE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FATE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FATE alerts
High impacting Fate Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FATE
News
- The $45 Billion Cell Therapy Boom Just Hit a Manufacturing Milestone Most Investors Haven’t NoticedGlobeNewswire
- Fate Therapeutics Details FT819 CAR T Manufacturing and Phase II Lupus Trial Plans at Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswire
FATE
Earnings
- 11/13/25 - Beat
FATE
Sec Filings
- 3/26/26 - Form SCHEDULE
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- FATE's page on the SEC website